Director Dealings

VERONA PHARMA PLC - Director Dealings

PR Newswire

London, June 17

Verona Pharma plc

(“Verona Pharma” or the “Company”)

Director Dealings

17 June 2015, Cardiff – Verona Pharma plc (AIM: VRP) today received notification that on 17 June 2015 David Ebsworth, Director of the Company, purchased 250,000 ordinary shares of 0.1 pence each of the Company (“Ordinary Shares”) at a price of 4.7 pence per Ordinary Share.

Following the transaction David Ebsworth has a total interest of 3,829,774 Ordinary Shares, representing 0.38% of the total voting rights.

-Ends-

For further information please contact:

Verona Pharma plc Tel: +44 (0) 20 3283 4200 Jan-Anders Karlsson, CEO N+1 Singer Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer FTI Consulting Tel: +44 (0)20 3727 1000 Julia Phillips / Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing.